ExploreOutcomeResting cerebral blood flow velocity
Outcome

Resting cerebral blood flow velocity

Also known as: Resting cerebral blood flow velocity at middle cerebral artery
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
conditions
populations
studys

Findings (27)

None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -
None
null

There was a trend for increased resting cerebral blood flow velocity in the candesartan group compared to declines in the lisinopril and HCTZ groups, but this did not reach statistical significance in

Effect: null; Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -2.40 cm/sec

Size: Candesartan: +1.03 cm/sec; Lisinopril: -2.12 cm/sec; HCTZ: -

Papers (1)